Compare ACT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACT | BLCO |
|---|---|---|
| Founded | 1981 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 2021 | 2022 |
| Metric | ACT | BLCO |
|---|---|---|
| Price | $40.64 | $17.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 14 |
| Target Price | ★ $40.67 | $17.31 |
| AVG Volume (30 Days) | 252.2K | ★ 369.2K |
| Earning Date | 02-03-2026 | 02-18-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 1.64 | N/A |
| EPS | ★ 4.36 | N/A |
| Revenue | $1,224,897,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $4.60 | $8.06 |
| Revenue Next Year | $3.50 | $5.79 |
| P/E Ratio | $9.33 | ★ N/A |
| Revenue Growth | 2.40 | ★ 6.23 |
| 52 Week Low | $30.79 | $10.45 |
| 52 Week High | $40.89 | $18.34 |
| Indicator | ACT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 58.68 |
| Support Level | $39.16 | $16.22 |
| Resistance Level | $40.69 | $17.55 |
| Average True Range (ATR) | 0.63 | 0.35 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 69.63 | 78.20 |
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.